Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

Paclitaxel 56Carboplatin 56Bevacizumab 43Gemcitabine 20Taxes 19pembrolizumab 15Immunoglobulin G 13Disulfides 13Topotecan 12olaparib 11Cisplatin 11niraparib 9Cyclophosphamide 9liposomal doxorubicin 8Specimen Handling 7Docetaxel 6Biopsy 6mirvetuximab soravtansine 5Nivolumab 5Magnetic Resonance Spectroscopy 5Letrozole 5Hyperthermic Intraperitoneal Chemotherapy 5Drug Therapy 5Cytoreduction Surgical Procedures 5Albumin-Bound Paclitaxel 5rucaparib 4pazopanib 4oregovomab 4Surgical Procedures, Operative 4Neoadjuvant Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Neoplasms × VTX-2337 × Clear all
NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Celgene

Phase 2 Completed
297 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡